UK-based liquid biopsy company Angle has partnered with Philips for the development of liquid biopsy solutions to diagnose breast and rectal cancers.
As part of the collaboration, Angle is set to receive £0.4m from a €6.3m (£5.58m) Horizon 2020 European Union (EU) research grant obtained by Philips.
Angle’s Parsortix system will also be used by Philips to harvest circulating tumour cells (CTCs) for analysis during their research.
Angle founder and chief executive Andrew Newland said: “We look forward to joint commercialisation of these solutions and to working closely with Philips going forward.
“This is a further demonstration of ANGLE’s strategy to partner with large corporates to deliver widespread adoption of ANGLE’s Parsortix CTC harvesting system.”
Planned for a total of four years, the partnership will see funding of £0.1m and £0.2m to Angle in the financial years ending 30 April 2018 and 2019, respectively.
Philips intends to spread the remaining £0.1m over the subsequent three financial years.
The EU research grant has been awarded to Philips and its consortium partners to develop an integrated technique for personalised cancer treatment as part of a four-year project, Liquid biopsies and Imaging for improved cancer care (LIMA).
LIMA’s purpose is to develop and validate tools and approaches for application in the early stages of cancer.
It is intended to enhance the accuracy of genetic and functional characterisation of the primary breast and rectal cancers by combining liquid biopsy and magnetic resonance imaging (MRI).
Clinical research studies to validate the new products will be conducted at the Universitair Medisch Centrum Utrecht in the Netherlands and the Institut National de la Sante et de la Recherche Medicale in France.